Background: Colorectal cancer (CRC) screening via colonoscopy is now advised for most adults beginning at age 45 years, an update from the earlier recommendation of age 50 years. With the increase in CRC screening rates, it is crucial to examine how mortality rates have changed over time. The aim of this study is to identify trends and regional differences in CRC mortality over the last two decades, specifically in individuals within the CRC recommended screening age group. Methods: This study used the Center for Disease Control’s Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) system to collect data on CRC mortality for people ages 45–84 years in the United States from 1999–2022. Results: During the study period, the overall age-adjusted mortality rate (AAMR) for CRC decreased across all census regions. The Midwest consistently had the highest AAMR, while the West had the lowest. Among genders, males in the Northeast had the highest rates, whereas females in the West had the lowest. Black or African Americans in the Midwest experienced the highest AAMR among racial groups, while Asian or Pacific Islanders in the Midwest had the lowest AAMR. Conclusions: The mortality rate of CRC has been decreasing since 1999, but differences between regional groups have persisted. Disparities in outcomes still exist, showing that vulnerable subgroups require targeted interventions such as improved screening and follow-up access to increase early-stage diagnoses and potential for curative treatments.
INTRODUCTION: Current guidelines suggest swallowable capsule-sponge devices with biomarkers can be used as alternatives to endoscopy for detecting Barrett's Esophagus (BE) in at-risk patients. We analyzed the screening performance of capsule-sponge with trefoil-factor-3 (TFF3) in patients with symptomatic acid reflux and assessed test performance across individual risk factors. METHODS: The study protocol was registered in Prospective Register of Systematic Reviews (PROSPERO) (CRD420250652091). Eligible studies reported results for both capsule-sponge-TFF3 and endoscopic assessment in adults with reflux symptoms and no history of BE. A systematic search was conducted through August 29, 2025. Two reviewers independently screened and extracted data using COllaboration + eVIDENCE (COVIDENCE). Risk of bias was assessed by QUality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Sensitivity and specificity were estimated in SAS v9.4 using bivariate mixed models allowing estimation of likelihood ratios, diagnostic odds ratios, and predictive values; meta-regression models were estimated for individual risk factors, acid suppressant use and BE prevalence. RESULTS: We identified 6 studies involving 1,454 participants in our meta-analysis. Pooled sensitivity for BE was 0.87 (95% CI: 0.80–0.94), specificity was 0.88 (95% CI: 0.80–0.95), negative predictive value at 20% prevalence was 0.96 (95% CI: 0.95–0.98), and the diagnostic odds ratio was 47.82 (95% CI: 44.99–50.83). Smoking and acid suppressant use were associated with increased specificity. DISCUSSION: Overall, our findings show that capsule-sponge-TFF3 is an effective minimally invasive screening tool for patients at risk of BE. Increased specificity in smokers may help reduce unnecessary endoscopies in this higher-risk group.